Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioFire Diagnostics

Explore full profile

A biotech company that detects pathogens and mutations for molecular diagnostics

Salt Lake City, United StatesFounded 1990Biotech & Life Sciences
Valuation $250–500M Last recorded · 2014
Headcount 500–1k Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BioFire Diagnostics and the history behind them.

About BioFire Diagnostics

BioFire Diagnostics, LLC, a leader in syndromic infectious disease testing, operates in the in vitro diagnostics market. This company specializes in molecular diagnostics, which involves analyzing biological markers in the genome and proteome to diagnose diseases. BioFire's flagship product, the BioFire System, is renowned for its speed, simplicity, and comprehensive testing capabilities. It can deliver accurate results in about one hour, making it a valuable tool for clinical laboratories that require around-the-clock molecular testing.

BioFire primarily serves clinical laboratories and healthcare providers who need rapid and reliable diagnostic tools to identify infections based on symptoms. The company’s syndromic testing approach allows for the simultaneous detection of multiple pathogens from a single patient sample, which is crucial for timely and accurate diagnosis. This method is particularly beneficial in identifying complex infections where symptoms may overlap, such as respiratory, gastrointestinal, and other infectious diseases.

The business model of BioFire Diagnostics revolves around the sale of its BioFire System and the associated test panels. These panels are designed to detect a wide range of pathogens, and the company generates revenue through the sale of these diagnostic kits. Additionally, BioFire offers ongoing support and maintenance services for its systems, ensuring that clients receive continuous and reliable performance.

BioFire Diagnostics operates globally, with FDA-cleared and CE IVD-marked assays, which means their products meet the regulatory standards in the United States and Europe. This global reach allows the company to support public health initiatives worldwide, reinforcing its mission to improve public health through advanced diagnostic solutions.

In summary, BioFire Diagnostics is a pioneering company in the field of molecular diagnostics, providing rapid and comprehensive syndromic testing solutions to clinical laboratories and healthcare providers. Their innovative BioFire System sets the standard for infectious disease diagnostics, ensuring accurate and timely results.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
1990
Headquarters
Salt Lake City, United States
Employees
608
Open positions
37
Dealroom signal
63.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, DNA, Infections and Infectious Diseases, Genetics and genomics, Molecular Biology, Health Diagnostics, Spinout, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b, b2c

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jan 2014 $450M $450M BioMérieux ↗
LATE VCOther financing May 2013 $45M $180M Athyrium Capital Management —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

BioFire Diagnostics website traffic

Latest recorded traffic for BioFire Diagnostics is 15K monthly website visits, down 34.8% over the last three months. BioFire Diagnostics's team declined 10.6% over the past year.

Latest monthly visits15K 3-month web change-34.8% 1-year team growth-10.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Athyrium Capital Management

Other known investors2 additional known investors

  • BioMérieux
  • University of Utah
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.5%
🏳️ Côte d'Ivoire0.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioFire Diagnostics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioFire Diagnostics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.